Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 41.62B |
| Revenue (ttm) | 31.73B |
| Net Income (ttm) | 2.02B |
| Shares Out | 1.59B |
| EPS (ttm) | 1.27 |
| PE Ratio | 20.56 |
| Forward PE | n/a |
| Dividend | $0.63 (4.84%) |
| Ex-Dividend Date | Sep 30, 2024 |
| Volume | 1,848,702 |
| Open | 13.04 |
| Previous Close | 13.01 |
| Day's Range | 13.02 - 13.19 |
| 52-Week Range | 12.58 - 15.08 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 30, 2025 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Financial Performance
In 2023, Takeda Pharmaceutical's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.
Financial numbers in JPY Financial StatementsNews
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Spotlights High-Value, Late-Stage Pipeline of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas.
Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors
Takeda Pharmaceutical offers a high dividend yield, but its sustainability is questionable due to exchange rate risks and a payout ratio often exceeding 100%. Despite growth in segments like Livtencit...
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept wo...
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to f...
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a s...
Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch
Masa Takeda, portfolio manager at Hennessy Japan Fund, joins CNBC's 'Power Lunch' to discuss why he's bullish on Japan, what president-elect Trump's proposed tariffs could mean for Japanese companies,...
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President an...
Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments
Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in it...
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center (BMC) today announced a new collaboration focused on identifying innovative solutions that can reduce...
Takeda Pharmaceuticals: An Interesting Option For Income Investors
Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The compan...
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaborati...
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and m...
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-...
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partner...
US allows increased production of Takeda's ADHD drug to address shortage
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing ...
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Monday, the FDA approved Ascendis Pharma A/S' ASND Yorvipath (palopegteriparatide; developed as TransCon PTH) for hypoparathyroidism in adults.
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Takeda Pharmaceutical Co Ltd TAK stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda's Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in child...
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 d...
Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q1 2025 Results Conference Call July 31, 2024 6:30 AM ET Company Participants Christopher O'Reilly - Head-Investor Relations Christophe Weber - Presid...
BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular Profiling
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immun...
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Grow...
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
Takeda Pharmaceutical Company Limited showed signs of improvement despite revenue declines in oncology and neurosciences, thanks to gains in gastrointestinal and inflammation sectors and strategic lea...
nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--nference announced a research alliance with Takeda aimed at harnessing AI to optimize patient care in inflammatory bowel disease.
Takeda Announces New Assignments of Directors
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting,...